• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MYX

MAYNE PHARMA GROUP LIMITED - Discussion

2.15% ! $2.85
Market Cap $226.6M  !
Healthcare Drug Manufacturers - Major
Add to My Watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Mayne Pharma Group Limited

edit-2 Created with Sketch. New Thread
refresh Created with Sketch. REFRESH
Forum Tag Subject View Poster Comments Created with Sketch. Views Created with Sketch. Likes Created with Sketch. Date Created with Sketch.
refresh Created with Sketch. REFRESH

Featured News

NEWS View the latest ASX news here
right-arrow Created with Sketch.
NEWS AI demand squeeze: investors' four big bottleneck bets
right-arrow Created with Sketch.
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
Start T rading
Last
$2.85 		Change
0.060(2.15%) 		Mkt cap ! $226.6M
Open High Low Volume
$2.81 $2.87 $2.79 122.0K

Buyers (Bids)

Vol. Price($)
1355 $2.85
 

Sellers (Offers)

Price($) Vol.
$2.86 3313
Last trade - 14.35pm 07/07/2026 (20 minute delay) ?
MYX (ASX) Chart

Top Stories

Expert Exchange: David Sokulsky on AI trade, chip stocks, and where to invest now

Carrara Capital CIO David Sokulsky on why he's bullish on AI but cautious on valuations, Nvidia, SK Hynix, and his top trading advice.
Invictus Energy awards high-impact Musuma-1 exploration well contracts Invictus Energy has awarded a number of key contracts in preparation for the drilling of the critical Musuma-1 exploration well in Zimbabwe.
Australia's resources and energy exports remain strong, despite Middle East crisis The AI investment boom is helping to generate demand for Australia’s resources and energy commodities according to new federal data.
Syntara shows encouraging first signals it can impact the path to Parkinson's Syntara (ASX:SNT) has reported encouraging interim results from its Phase 2 study of SNT-4728, providing the first clinical evidence that the company’s novel anti-inflammatory therapy may be targeting a key biological process linked to the development of Parkinson’...
LISTEN: HotCopper Wire Podcast #052 – Finger lickin' not so good In this week’s HotCopper Wire episode, Isaac McIntyre and Jonathon Davidson talk about all the inflation data that’s come out in Australia this week and whether the Reserve Bank will go for another hike in August, as well as the H5 bird flu scare in WA @ and what t...

Featured News

NEWS View the latest ASX news here
right-arrow Created with Sketch.
NEWS AI demand squeeze: investors' four big bottleneck bets
right-arrow Created with Sketch.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.